BZBing Zhou
Papers(2)
Post-uterine artery e…FNDC5 inhibits malign…
Collaborators(1)
Guo‐Qing Zhu
Institutions(2)
Affiliated Hospital O…Nanjing Medical Unive…

Papers

Post-uterine artery embolization: 3-day MRI changes and their predictive value for therapeutic efficacy in symptomatic uterine fibroids

Abstract Objectives To summarize and discuss 3-day MRI changes after uterine artery embolization (UAE) and their predictive value for efficacy. Methods From August 2016 to April 2023, 52 patients underwent enhanced MRI within 3 days post-embolization. We retrospectively analysed clinical and imaging data, focusing on MR characteristics at the 3-day mark, comparing pre- and post-embolization images. Patients were categorized based on 3-day MR findings into complete and incomplete necrosis groups, with clinical efficacy compared over 6 months. Results Our study included 30 cases of multiple leiomyomas and 22 of single leiomyomas. Postoperative MRI revealed complete necrosis in 31 tumours and incomplete necrosis in 21 tumours. At 3 days, MR ADC imaging showed increased signals in necrotic areas, mildly increased signals on T2-weighted images, and minimal changes on T1-weighted images. Six-month follow-up showed no significant difference in symptom improvement between groups (P = .524, P = .587, P = .615). However, a significant difference was found in leiomyoma volume reduction, with 70.63 ± 15.53% in the complete necrosis group and 51.36 ± 25.20% in the incomplete necrosis group (P < .001), highlighting the impact of necrosis extent on volumetric reduction. Conclusion Short-term MRI changes after UAE can reflect changes in blood supply to fibroids and normal uterine tissue, and have good predictive value for medium-term embolization efficacy. Advances in knowledge This study describes short-term MR manifestations of complete and incomplete embolism, aiding in predicting long-term outcome.

FNDC5 inhibits malignant growth of human cervical cancer cells via restraining PI3K/AKT pathway

AbstractCervical cancer (CxCa) is the fourth most frequent cancer in women. This study aimed to determine the role and underlying mechanism of fibronectin type III domain‐containing protein 5 (FNDC5) in inhibiting CxCa growth. Experiments were performed in human CxCa tissues, human CxCa cell lines (HeLa and SiHa), and xenograft mouse model established by subcutaneous injection of SiHa cells in nude mice. Bioinformatics analysis showed that CxCa patients with high FNDC5 levels have a longer overall survival period. FNDC5 expression was increased in human CxCa tissues, HeLa and SiHa cells. FNDC5 overexpression or FNDC5 protein not only inhibited proliferation, but also restrained invasion and migration of HeLa and SiHa cells. The effects of FNDC5 were prevented by inhibiting integrin with cilengitide, activating PI3K with recilisib or activating Akt with SC79. FNDC5 inhibited the phosphorylation of PI3K and Akt, which was attenuated by recilisib. PI3K inhibitor LY294002 showed similar effects to FNDC5 in HeLa and SiHa cells. Intravenous injection of FNDC5 (20 μg/day) for 14 days inhibited the tumor growth, and reduced the proliferation marker Ki67 expression and the Akt phosphorylation in the CxCa xenograft mouse model. These results indicate that FNDC5 inhibits the malignant phenotype of CxCa cells through restraining PI3K/Akt signaling. Upregulation of FNDC5 may play a beneficial role in retarding the tumor growth of CxCa.

14Works
2Papers
1Collaborators

Positions

Researcher

First Affiliated Hospital of Wannan Medical College

Education

2020

Nanjing Medical University

2015

Wannan Medical College

Country

CN